Date: 2011-06-01
Type of information: Private placement
Company: Bioinvent International (Sweden)
Investors:
Amount: SEK 136 million (€15.16 million)
Funding type: private placement
Planned used: The proceeds are intended to be used for general corporate purposes and to fund development of the current clinical pipeline.
Others: Bioinvent International has completed a private placement of 6,109,568 new shares, providing the company with approximately SEK 136 million (€15.16 million) before transaction costs. The private placement, which was announced on 31 May 2011, has allowed BioInvent to place 6,109,568 new shares at a price of SEK 22.30 per share with international institutional investors and qualified investors in Sweden through an accelerated bookbuilding procedure (the “Private Placement”). The majority of the investors were international. Through the issue, the number of shares in BioInvent increases by 6,109,568 from 61,095,689 to 67,205,257 and the share capital increases with SEK 3,054,784 from SEK 30,547,844.50 to SEK 33,602,628.50.
Therapeutic area: Cancer - Oncology
